Dulaglutide
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus (T2DM)
Conditions
Type 2 Diabetes Mellitus (T2DM)
Trial Timeline
Dec 29, 2025 → Aug 1, 2026
NCT ID
NCT07313813About Dulaglutide
Dulaglutide is a phase 1 stage product being developed by Eli Lilly for Type 2 Diabetes Mellitus (T2DM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07313813. Target conditions include Type 2 Diabetes Mellitus (T2DM).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07313813 | Phase 1 | Recruiting |
| NCT06739122 | Phase 3 | Recruiting |
| NCT05659537 | Approved | Completed |
| NCT03495102 | Phase 3 | Completed |
| NCT01524770 | Phase 1 | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus (T2DM)